Independent DSMB reports zero device-related safety issues Supports potential clinical benefit Trial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- ...

Objectives C reactive protein (CRP) is frequently normal in psoriatic arthritis (PsA) despite active disease, complicating ...

Brazil has approved a new law to partially prohibit live animal testing for cosmetics, and will instead prioritize ...

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide, largely due to the limited efficacy of ...

The FDA has approved a subcutaneous (SC) induction regimen of guselkumab (Tremfya) for adults with moderately to severely ...

Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous ...

Johnson & Johnson announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA for the treatment ...

Levels of systemic inflammatory markers were reduced following 16 weeks of secukinumab treatment in patients with moderate to severe HS.

Developed by Johnson & Johnson, guselkumab is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.

Trinity College Dublin scientists showed that electrical stimulation reprograms macrophages to reduce inflammation and boost healing. This breakthrough could lead to broad therapeutic uses.

In almost all solid tumors—i.e. cancers with a solid tissue structure—the detection of tumor cells in the lymph nodes is ...